Virupaksha Organics Limited IPO Details

Incorporated in 1997, Virupaksha Organics is a research-driven Indian pharmaceutical company that makes active pharmaceutical ingredients (APIs), key starting materials (KSMs), and intermediates.

Along with APIs and intermediates, it also provide contract development and manufacturing (CDMO) services to third-party pharma companies. As of March 31, 2025, the company offer 54 products (23 APIs and 31 intermediates) across a wide range of therapeutic areas such as anti-histamines, analgesics, anti-fungals, anti-diabetics, anti-depressants, anti-asthmatics, and more.

It serve over 550 customers in more than 100 countries, including large multinational pharmaceutical companies in the US, Europe, and Japan. Many of its customer relationships span over eight years. The company have also filed 25 drug master files (DMFs) across global markets, including 11 with the USFDA.

The operations are supported by six manufacturing units in Telangana and Karnataka with 223 reactors and a total capacity of 988 KL. The company uses advanced technologies such as flow chemistry, VapourTech reactors, infrared spectroscopy, NMR, mass spectrometry, and x-ray diffraction to maintain product quality and safety.

As of March 31, 2025, the company employed 978 permanent employees.

Competitive strengths

• Comprehensive product portfolio
• Diversified global customer base with long-standing relationships with key customers
• Robust manufacturing units, backed by our strong research and development capabilities
• Experienced promoters and management team